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Antioxidants have been used as therapies to decrease
oxidative stress and improve CVD risk in hemodialysis (HD)
patients. A systematic search of the Medline database (search
date 30 April 2011) found 56 studies investigating the effects
of antioxidant therapies on biomarkers of oxidative stress
(53 studies) or clinical outcomes (3 studies). The majority
were small trials using a nonrandomized open-label design
with a single HD group (no HD controls). Alpha-tocopherol
was the most investigated antioxidant, with 20/25 studies
reporting that this vitamin decreased oxidative stress, and
one clinical outcome trial in 196 patients finding that it
protected against secondary CVD. Studies using vitamin
C were more equivocal, with 4/11 showing decreased
oxidative stress and one clinical outcome trial showing no
effect on morbidity or mortality. N-acetylcysteine was the
most efficacious agent, with 4/4 studies indicating a decrease
in oxidative stress and one trial (n¼ 134) showing reduced
CVD events. Seven studies have used therapy containing a
combination of antioxidants, with five of these reporting
decreased oxidative stress. Most intervention studies in HD
patients, such as statin therapy and increased dialysis dose,
have failed to show improvement in CVD outcomes.
Two intervention trials using different antioxidants have
found CVD benefits, suggesting that this line of therapy is
effective in this resistant population. These studies require
validation in larger, adequately powered trials.
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Cardiovascular disease (CVD) is the cause of death inB34%
of hemodialysis (HD) patients.1 Indeed, at all ages, these
individuals have a 10- to 20-fold increased risk of death from
CVD.2 Clinical trials using a range of interventions aimed
at improving CVD outcomes in HD patients have been
unsuccessful. These include the use of lipid-lowering therapy
in the AURORA trial3 and 4D trial,4 increased dialysis dose in
the HEMO trial,5 and the timing of dialysis initiation in the
IDEAL trial.6 The only two intervention trials to show a
positive effect in this population were those using antioxidant
therapy.7,8 This, combined with evidence that oxidative stress
is increased in HD patients and associated with CVD in this
population,9 suggests that antioxidant therapy may improve
the CVD morbidity and mortality of HD patients. The aims
of this review were to systematically appraise the evidence
regarding the effects of antioxidant therapy on oxidative
stress in HD patients, synthesizing data from biochemical-
based studies and a small number of CVD outcome trials.
BACKGROUND
Oxidative stress
Oxidative stress refers to the situation in which pro-oxidants
overwhelm antioxidant defenses, resulting in increased
biomarkers of oxidative damage. Pro-oxidants, commonly
referred to as reactive species, include reactive oxygen species
and reactive nitrogen species, of which the most common
reactive nitrogen species is nitric oxide. The reactive oxygen
species consist of free radicals, molecules lacking a paired
electron in their outer orbital such as the superoxide anion
and hydroxyl radical, and other oxygen-derived molecules
such as hydrogen peroxide and hypochlorous acid.10 Reactive
species have a complex role in health and disease, highlighted
by providing the stimulus to relax blood vessels.11 When
antioxidant capacity is overwhelmed, numerous compounds
such as lipids, proteins, carbohydrates, and DNA become
susceptible to oxidative damage. Oxidation of circulating
lipids, such as low-density lipoproteins (LDLs), is implicated
in the pathogenesis of vascular disease through the formation
of atherosclerotic plaque.12
Antioxidants
The body’s antioxidant defenses are endogenous and
exogenous (dietary and therapeutic). Dietary antioxidants
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include vitamin E, vitamin C (ascorbic acid), and b-carotene.
Vitamin E refers to eight structurally similar compounds,
a-, b-, g-, and d-tocopherol, and a-, b-, g-, and
d-tocotrienol. The a-tocopherol has the highest biological
activity and is therefore often referred to as vitamin E. The
a-tocopherol and b-carotene are lipid-soluble molecules,
whereas vitamin C resides in the aqueous phase. Importantly,
many antioxidants exhibit synergistic relationships with other
antioxidants; for example, vitamin C is capable of recycling
a-tocopherol. Therapeutic antioxidants include compounds
such as N-acetylcysteine and bardoxolone.13
Antioxidants and cardiovascular disease
Evidence for the beneficial effects of antioxidants on CVD is
found in observational studies such as the World Health
Organization’s MONICA (MONitoring trends and determi-
nants In CArdiovascular disease) Study,14 the Nurses Health
Study,15 the US Physicians study,16 and randomized
controlled clinical trials such as CHAOS (Cambridge Heart
AntiOxidant Study).17 However, large trials including the
HOPE (Heart Outcomes Prevention Evaluation) trial18 and
the Heart Protection Study19 have not supported the notion
that antioxidants provide CVD protection. Proponents of
antioxidants speculate that these therapies would be most
beneficial in individuals with chronically elevated oxidative
stress rather than the general population.20
Oxidative stress in HD patients
HD patients have elevated oxidative stress compared
with healthy matched controls, and this is postulated
as contributing to the high levels of CVD morbidity and
mortality in these individuals.9 Indeed, numerous studies,
included in this review, have compared oxidative stress
between HD patients and controls. The markers of oxidative
stress shown to be elevated include F2-isoprostanes,
21
lipid hydroperoxides,22 oxidized anti-LDL antibodies,23 the
oxidizability of LDL,24 free sulfhydryl groups,25 carbonyl
groups,26 3-chlorotyrosine,27 and advanced oxidation protein
products.28
Figure 1 shows that oxidative stress may be increased
because of a loss of antioxidants during dialysis,29 interac-
tions between blood and dialysis membrane,30 bacterial
products in dialysate crossing the dialysis membrane directly
or indirectly stimulating release of reactive species by
neutrophils, and malnutrition decreasing the uptake of
dietary antioxidants.31 On the basis of the evidence of
elevated oxidative stress in predialysis chronic kidney disease
patients, it is evident that the disease itself contributes to this
state.32 Indeed, a recent study showed that estimated
glomerular filtration rate, inflammation, and high-density
lipoprotein cholesterol were the main determinants of
elevated reactive species production in nondialysed CKD
patients.33 In addition, HD activates immune cells and
increases production of reactive oxygen species, leading to an
acute inflammatory response and oxidative stress. Both
processes are involved in the pathogenesis of atherosclerotic
CVD.34 Therefore, therapies that reduce production of these
damaging molecules or decrease their ability to cause damage
may improve the CVD morbidity and mortality of HD
patients. Plasma levels of vitamin E are decreased during HD,
suggesting that vitamin E therapy may improve biomarkers
of oxidative stress in this patient population.35,36
SYSTEMATIC REVIEW
Methods
A comprehensive literature search was completed on 30 April
2011 using the Medline database (PubMed) with the
following MESH headings and search terms: dialysis AND
antioxidants OR vitamin E OR tocopherol OR vitamin C OR
ascorbic acid OR selenium OR acetylcysteine OR vitamin A
OR beta-carotene OR coenzyme Q10; the limits included
the following: humans and clinical trials. Only the studies
that investigated the effects of oral antioxidant therapy on a
marker/s of oxidative stress or a CVD outcome measure
in patients undergoing HD were included. Studies using
vitamin-E-coated dialyzer membranes or those that only
looked at changes in plasma antioxidant levels were not
included. Owing to the large variety of oxidative stress
outcome measures, a meta-analytical approach was not
possible. Antioxidants were considered to have had a positive
effect if administration was associated with a significant
decrease of a biomarker or biomarkers of oxidative stress.
Of the 298 articles identified, 56 original investigation
articles met the criteria for inclusion in this review. Of these,
53 assessed the effects of antioxidant therapy on a biomarker
or biomarkers of oxidative stress (Tables 1–4), whereas
additional 3 studies investigated the effects of antioxidants on
CVD end points (Table 5). Summary tables have been
divided into those using a-tocopherol (Table 1, 25 studies),
vitamin C (Table 2, n¼ 11), and others (Table 3).
General considerations
The timing of blood collection for oxidative stress biochem-

















Figure 1 |Mechanisms resulting in elevated oxidative stress in
hemodialysis patients.
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findings. In the 53 studies in which oxidative stress was
measured, most (35 studies) were designed to compare data
from blood samples collected shortly after initiation of the
HD session, before and after the therapeutic period. Blood
samples are usually withdrawn immediately after dialysis
needles are inserted. In the tables, these are described as
Comparing predialysis data. Some (9 studies) have taken
blood samples at or near the end of dialysis to compare the
change in the measures before and after the dialysis
session before and after the therapeutic period. These are
described as Comparing changes from pre- to postdialysis.
In addition, four of these nine studies have investigated
the changes in oxidative stress measures from postdialysis
before and after therapy, herein described as Comparing
postdialysis.
Substrates investigated for oxidative damage included
lipids (44 studies), proteins (seven studies), and DNA
(1 study). Malondialdehyde (MDA) was the most common
lipid oxidation biomarker measured directly or estimated
from the thiobarbituric acid reactive substances assay
(27 studies). Assays involving isolated LDL cholesterol were
the second most common marker (n¼ 10 studies), followed
by isoprostanes (n¼ 4 studies), protein carbonyls (n¼ 4
studies), and lipid hydroperoxides (n¼ 3 studies). In total,
over 20 different oxidative stress biomarkers were used across
the 55 studies. Unfortunately, there is no longitudinal
evidence to support the use of any of these as a definitive
biomarker of clinical outcomes in any population. In a recent
review from our group, it was found that oxidative stress
biomarkers failed to predict CVD in prospective studies using
a variety of disease and nondisease populations.37
FINDINGS
The majority of the 53 studies (37 studies) showed a decrease
in biomarkers of oxidative stress following antioxidant
therapy, whereas 15 showed no effect and 8 found an
increase. Some studies assessed more than one oxidative
stress biomarker. Of the 37 studies that showed decreased
oxidative stress, 20 used a-tocopherol.
a-Tocopherol
The 25 studies investigating the effects of a-tocopherol on
oxidative stress in HD patients are presented in Table 1,35,38–61
although these represent only 17 different trials. For example,
the first five reports published in this area (1984–1992) are all
from an Italian research group that administered 300 mg/day
of intravenous a-tocopherol for 15 days and reported
decreases in erythrocyte MDA,38,39 peripheral blood mono-
nuclear cell MDA,40 and platelet MDA.41 Articles from the
same trial are highlighted with the same superscript symbol
in Table 1.
a-Tocopherol was reported to decrease oxidative stress in
20 of the 25 included studies. Of these studies, 19 measured
changes in circulating a-tocopherol after therapy, with 18
studies reporting significant increases in different compart-
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The gold standard for a clinical therapeutic trial is the
randomized controlled trial (RCT), which is placebo
controlled and blinded. The first RCT investigating the
effects of a-tocopherol on oxidative stress in HD patients was
not reported until 2005,58 after 20 open-labeled/noncon-
trolled/nonrandomized studies had been published. Indeed,
only 3 of the 25 studies shown in Table 1 used an RCT
design.58–60 The three RCTs included a total of 95 patients.
The first of these used a factorial design and combined
a-tocopherol (800 IU/day for 12 weeks) with atorvastatin
(40 mg/day).58 The investigators found no effect of
a-tocopherol on plasma-oxidized LDL. Lu et al.60 also
administered 800 IU/day, but over a 6-month period, with
results showing no effect on oxidative protein products. In
the other RCT, Uzum et al.59 used 300 mg/day for 20 weeks
and reported decreased erythrocyte osmotic fragility and
decreased plasma MDA.
Dosages. In the 20 studies that demonstrated decreased
biomarkers of oxidative stress, the mean dose administered
wasB500 mg/day, with the lowest 15 IU/day and the highest
1200 IU/day. The conversion from IU to mg is between 0.9:1
and 1.5:1 depending on the form of a-tocopherol, and, as
discussed below, unfortunately most studies do not report
the form of a-tocopherol used. In studies showing that
a-tocopherol had no effect, the doses used were between
200 mg/day57 and 800 IU/day.51,60 Therefore, within this
dose range, a-tocopherol appears to have had limited effect
on oxidative stress in HD patients.
Form. The form of a-tocopherol administered, either
natural or synthetic, may be a factor influencing
its effectiveness.62 Unfortunately, the majority of studies did
not specify the form administered, and in those that did, one
used synthetic48 and four used a natural form.50,51,56,60 Thus,
there are insufficient data to comment on the efficacy of the
different forms of a-tocopherol.
Duration. There were no differences in the median
duration of therapeutic periods in the studies showing that
a-tocopherol decreased oxidative stress compared with those
reporting no effect, with both being 8 weeks.
Vitamin C
Compared with studies using a-tocopherol, the effects of
vitamin C in HD patients were more equivocal. Across the 11
studies (n¼ 371 patients, Table 2) of which 9 used an RCT
design,63–71 vitamin C was reported to decrease oxidative
stress in 4,63,66,69,71 increase oxidative stress in 3,64,65,72 and
have no significant effect in the other 4 studies.67,68,70,73 All
but two studies70,72 measured plasma vitamin C and reported
that therapy increased these levels.
Dosages, durations, and routes of administration. The
doses, duration, and routes of administration of vitamin C
may explain the differences in findings across the studies. In
studies showing decreased oxidative stress, 250 mg/day and
1 g/day were given orally for 12 weeks63 and 1 year,70
respectively, and intravenous doses of 300 mg/day were
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However, in the three studies showing increased oxidative
stress, two used a single intravenous dose.64,65 Vitamin C has
known reactions with metal ions that may exacerbate oxidative
stress. This may occur after a single vitamin C dose. However,
over time, there are adjustments to defenses that eventually
result in a more pronounced antioxidant effect. In the other
study showing elevated oxidative stress with administration of
vitamin C, doses were increased from 200 mg to 1 g/day over a
period of 3 months.70 The increased dose may have a similar
effect as the single dose, with insufficient time to enable other
antioxidant defenses to compensate. However, in the four
studies with no change in oxidative stress, time periods ranged
from 4 to 12 weeks.67,68,70,73 This suggests that even after these
time periods vitamin C is ineffectual. All four of these studies
used 250 mg/day, suggesting that this dose may be insufficient
to alter oxidative stress.
N-acetylcysteine
Four studies (three RCTs) comprising 172 subjects have
administered N-acetylcysteine, with all studies showing that
it decreased oxidative stress.74–77 The doses used varied from
1.2 g/day in two studies74,76 to 2 g/day77 and to 5 g/day75 in
the other two studies, whereas therapy duration ranged from
a one-off dose75 to 3 weeks.74 N-acetylcysteine is known as an
antidote for acetominphen overdose. However, other clinical
applications include preservation of lung function in chronic
obstructive pulmonary disease and prevention of contrast-
induced kidney damage during imaging procedures.78 The
therapy with N-acetylcysteine increases the endogenous
antioxidant glutathione by contributing cysteine to support
its synthesis.79 In addition to the antioxidant properties of
N-acetylcysteine, it also facilitates the production and action
of nitric oxide, leading to improved vasodilation.80 Indeed,
two of the four studies showed that N-acetylcysteine decreased
asymmetric dimethylarginine,75,81 indicating that the oxidative
stress effect is likely to lead to enhanced endothelial function.82
Selenium
Although toxic in large doses, selenium is an essential trace
element that functions as a cofactor for the reduction of
antioxidant enzymes such as glutathione peroxidase. The
antioxidant benefits of selenium are purported to occur via
upregulation of the activity of this enzyme.83 Table 3 shows
that three small noncontrolled studies in a total of 40 HD
patients investigated selenium therapy, with two finding
decreased biomarkers of oxidative stress84,85 and one finding
no effect.86 All three showed increased circulating selenium
levels. Doses ranged from 25 mg orally to 400 mg85 via
intravenous route, and durations were 8 weeks85 and 20
weeks.84 More investigation is required before selenium
therapy could be recommended in HD patients.
Other antioxidants
Himmelfarb et al.87 used an RCT to investigate the effects of
g-tocopherol and docosahexaenoic acid on oxidative stress in
63 HD patients. This group chose to measure the oxidative
stress biomarkers plasma isoprostanes and protein carbonyls.
Eight weeks of therapy had no significant effect on either.
In the final two studies listed in Table 3, both a-lipoic
acid81 and coenzyme Q10 (see ref. 88) had differential effects
on oxidative stress. The a-lipoic acid decreased plasma
asymmetric dimethylarginine but had no effect on oxidized
LDL, and coenzyme Q10 decreased plasma advanced
oxidation end products but did not change plasma MDA.
These two studies highlight the importance of the choice of
the oxidative stress biomarker.
Antioxidant combinations
There are plausible reasons why combining different
antioxidants may provide greater benefits. Some antioxidants
work in synergy (for example, vitamin C recycles
a-tocopherol) and have different properties (for example,
vitamin C is water soluble, whereas a-tocopherol is found in
the lipid phase). Therefore, given the complexity of oxidative
stress, there has been interest in providing therapies
combining antioxidants. Table 4 contains details of seven
studies describing six trials that investigated the effects of
combinations of antioxidants on oxidative stress. Four
studies reported decreased oxidative stress,89–92 two found
no effect,93,94 and one reported a decrease in one biomarker
but no change in another.95 It is interesting to note that
a-tocopherol was used in six of the studies,89,90,92–95 with five
of these adding vitamin C.89,90,93–95 Only one of the seven
studies used an RCT design with an identical placebo as the
control, and this found no effect of an antioxidant
combination containing a-tocopherol and vitamin C taken
for 8 weeks.93
There is increasing interest in the use of foods high
in antioxidants as dietary antioxidant supplements. Red
grape juice contains phytochemicals such as resveratrol, a
polyphenol antioxidant that has possible roles in CVD and
cancer prevention.96,97 Two studies from the same research
group investigated the effects of red grape juice on oxidative
stress in HD patients. Both showed decreases in oxidized
LDL, possibly indicating reduced risk of atherosclerotic
plaque formation.91,92
Clinical outcome trials
Table 5 provides details of three trials investigating the effects
of antioxidant therapy on clinical outcomes. The most cited
of these is the SPACE (Secondary Prevention with Antiox-
idants of Cardiovascular disease in End-stage renal disease)
trial.7 Indeed, at the time of the systematic search for this
review article, there were more than 500 citations. In this ran-
domized, double-blind, placebo-controlled trial, 97 patients
were treated with 800 IU a-tocopherol/day for B500 days,
with 99 patients receiving placebo. The major findings were
a 54% reduction in cardiovascular risk (P¼ 0.014), a 40%
reduction in composite CVD end points, and a 70%
reduction in total myocardial infarction (P¼ 0.014 and
0.016, respectively). The authors report baseline MDA values,
but did not have control values from normal individuals to
242 Kidney International (2012) 81, 233–246
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judge whether the trial participants actually had oxidative
stress. This was noted in a subsequent letter to the editor
suggesting that the lack of a healthy control group made these
data less meaningful.98 The investigators responded and
agreed that useful insights into the mechanisms of effects
could have been provided had they included a more
comprehensive assessment of oxidative stress.99 In this letter,
they provide end point data of MDA levels showing that the
placebo group had a 10% increase and that the a-tocopherol-
treated group had a 2% decrease. They caution that the small
sample size (n¼ 15) does not provide sufficient statistical
power. Although there are acknowledged deficiencies in the
SPACE Study, the outcomes of secondary CVD prevention in
HD patients are important and require substantiation in a
larger population.
Tepel et al.8 performed an RCT in which 64 patients
were treated orally with 1.2 g/day of N-acetylcysteine for 14
months, with 70 patients taking the placebo. Their results
support the protective effects of antioxidants, with evidence
of reduced rates of CVD events. However, there were no
differences in secondary end points (total mortality and CVD
mortality). In contrast to the two positive studies, the first
clinical outcome trial in HD patients was a noncontrolled
study in 61 patients, published by Ono100 in 1989. This
investigator administered 500 mg/day of vitamin C for 2
years, but found no difference in morbidity or mortality
rates. An important issue regarding the three trials is that
none reported changes in oxidative stress. In addition, the
presence of oxidative stress was not an inclusion criterion for
these trials. It is therefore likely that many patients in these
trials were potentially not in a biochemical state that would
benefit from additional antioxidant defenses. Indeed, there is
increasing evidence that antioxidant therapy can lead to
deleterious cell functions and adverse health benefits in this
situation.101 In most pharmaceutical trials, inclusion criteria
specifically ensure that patients will be selected to represent
the target group and maximize the potential benefit of the
intervention (for example, a blood pressure drug trial does
not include people with normal/low blood pressure). It will
be interesting to see the findings of antioxidant therapy
intervention trials designed with elevated oxidative stress as
an inclusion criterion and where the administered antiox-
idant actually reduces the biomarker of oxidative stress.102
FUTURE STUDIES
One of the biggest handicaps for research in this area is the
lack of a clinically accepted and validated oxidative stress
biomarker. Given this, it is not surprising that there is
insufficient evidence to support the association between any
of the currently used measures and clinical outcomes. Unlike
the case with inflammation, where the clinician can request a
measurement of C-reactive protein, it is not possible to
routinely order an oxidative stress measure from a pathology
department. Currently, these measures are conducted in
research laboratories and there is no standardization or
accepted control values, making the interpretation difficult.
Furthermore, because of the nature of some assays, values
across different studies are not comparable. This increases
the importance of including a healthy control group as a
comparator.
There is a risk that poorly constructed studies with
negative outcomes might result in failure to recognize
potentially effective therapies. The steps, shown in Figure 2,
are proposed to increase the likelihood of finding a
cardiovascular benefit of antioxidant therapy in HD patients.
Because of the complexity of oxidative stress, it is likely that
one measure may not be sufficient and a panel of biomarkers
may be needed to encompass the different types of oxidative
damage (for example, lipid, protein, DNA) and perturbations
to antioxidant defenses. Testing of oxidative stress biomarker/s
in longitudinal studies is necessary to determine sensitivity
and specificity in predicting CVD outcomes in HD patients.
Once established, time-course and dosing studies of anti-
oxidant therapy should be tested to ensure that the desired
reduction in oxidative stress is achieved. Finally, an appro-
priately powered antioxidant intervention RCT could be
designed with the presence of oxidative stress as an inclusion
criterion.
SUMMARY
Intervention studies to reduce CVD morbidity and mortality
in HD patients have been mainly unsuccessful. Only two such
studies reported a positive therapeutic effect, and these
studies have used the antioxidants a-tocopherol and N-
acetylcysteine.7,8 Despite this, there have been no recom-
mendations for their use and no follow-up studies to confirm











efficacy in HD patients
Determine optimal form, dose,
and time course to decrease
oxidative stress to normal values
RCT with CVD morbidity
and mortality outcomes
Figure 2 | Flowchart indicating that future studies need to first
develop valid oxidative stress biomarkers before evaluating
the efficacy of antioxidant therapy. CVD, cardiovascular disease;
HD, hemodialysis; RCT, randomized controlled trial.
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the effects of antioxidant therapy in HD patients. As a wide
variety of antioxidants, dosages, forms, and durations
have been used, recommendations regarding therapy are
not currently possible. The majority of studies have used
a-tocopherol and found that it decreased oxidative stress,
and one clinical trial showed protection against CVD.
N-acetylcysteine has consistently decreased oxidative stress
and its potential use is supported by a clinical trial in which
CVD protection was demonstrated. The findings of these
positive clinical trials need to be confirmed before the
widespread use of this therapy. Such promising results
require urgent further investigation in this population, which
has limited therapeutic options and poor outcomes.
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